孟鲁司特钠与特布他林联合治疗儿童咳嗽变异性哮喘临床疗效分析

Clinical efficacy of montelukast sodium combined with terbutaline in treatment of children with cough variant asthma

目的探讨孟鲁司特钠联合特布他林对儿童咳嗽变异性哮喘伴肺炎支原体感染的临床治疗效果,并观察其安全性,为临床治疗提供依据。方法选择2012年3月-2014年3月医院收治的咳嗽变异性哮喘伴肺炎支原体感染患儿112例,根据治疗方法将患儿分为对照组和观察组,各56例,两组患儿均给予阿奇霉素治疗,对照组给予特布他林雾化吸入;观察组给予口服孟鲁司特联合特布他林雾化吸入治疗;主要评估两组治疗效果、评估治疗前后患儿咳嗽和睡眠评分、评估治疗期间患儿肺功能指标及不良反应。结果治疗显效率观察组为73.21%,高于对照组58.93%,差异有统计学意义(P<0.05);观察组患儿咳嗽消失和喘憋消失时间均低于对照组,差异有统计学意义(P<0.05);观察组患儿治疗期间FEV1、PEF和FEV1/FVC分别为(2.97±0.62)L、(96.61±4.17)%和(71.84±2.76)%均高于对照组,差异有统计学意义(P<0.05);观察组患儿治疗后咳嗽和睡眠评分均低于对照组,且两者治疗后均低于治疗前,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义。结论孟鲁司特钠联合特布他林治疗儿童咳嗽变异性哮喘伴肺炎支原体感染临床疗效较好,能够显著改善患儿的临床症状或体征,并具有安全性,值得临床推广。

OBJECTIVE To explore the clinical effect of montelukast sodium combined with terbutaline on treatment of the children with cough variant asthma and observe the safety so as to provide guidance for the clinical treat‐ment .METHODS A total of 112 children with cough variant asthma complicated with Mycoplasma pneumoniae in‐fection ,who were treated in the hospital from Mar 2012 to Mar 2014 ,were recruited as the study objects and di‐vided into the control group and the observation group according to the treatment method ,with 56 cases in each ;both groups were treated with azithromycin ,the control group was given the aerosol inhalation of terbutaline ,the observation group was treated with oral administration of montelukast sodium combined with aerosol inhalation of terbutaline;the curative effect ,cough and sleeping score before and after the treatment ,pulmonary function indi‐cators during the treatment ,and adverse reactions were observed and evaluated .RESULTS The effective rate of treatment of the observation group was 73 .21% ,higher than 58 .93% of the control group ,there was statistically significant difference （P〈0 .05）;the time of disappearance of cough and wheezing of the observation group was shorter than that of the control group ,there was statistically significant difference （P〈0 .05） .During the treat‐ment ,the FEV1 ,PEF ,and FEV1/FVC of the observation group were respectively （2 .97 ± 0 .62）L ,（96 .61 ± 4 .17）% ,and（71 .84 ± 2 .76）% ,higher than those of the control group ,with statistical significance （P〈0 .05） .The cough and sleeping score of the observation group was lower than that of the control group after the treatment ,and the score of both groups was lower after the treatment than before the treatment ,the difference was statistically significant （P〈 0 .05） .As compared with the incidence of adverse reactions ,there was no statistically significant difference between the two groups .CONCLUSION The montelukast sodium combined with terbutaline can achieve good clinical efficacy in treatment of the children with cough variant asthma complicated with Mycoplasma pneumoniae infection and remarkably improve the clinical symptoms and signs ,and it is safe and worthy to be promoted in the hospital .